In a patient with unexplained proteinuria, hematuria and declining renal function suggestive of glomerulonephritis, why are serum complement C3 measurement and an alternative pathway functional assay important for diagnosis, prognosis, and guiding therapy?

Why C3 and Alternative Pathway Assessment Are Critical in Kidney Disease Evaluation

Immediate Diagnostic Imperative

Serum C3 measurement and alternative pathway functional assays are essential because they distinguish between fundamentally different disease mechanisms—immune complex-mediated glomerulonephritis requiring immunosuppression versus complement-mediated C3 glomerulopathy requiring complement-targeted therapy versus infection-related disease requiring antimicrobials—each demanding completely different treatment strategies that directly impact patient survival and renal outcomes. 1, 2, 3

Core Diagnostic Algorithm: C3 Pattern Recognition

Isolated Low C3 (Normal C4)

• Alternative pathway activation is the defining feature when C3 is low but C4 remains normal, immediately narrowing your differential to post-infectious glomerulonephritis, C3 glomerulopathy, or infection-related glomerulonephritis. 2

• Temporal monitoring distinguishes acute from chronic disease: C3 normalizes within 8–12 weeks in post-streptococcal glomerulonephritis, whereas persistent depression beyond 12 weeks mandates kidney biopsy to evaluate for C3 glomerulopathy. 2, 3

• Bacterial endocarditis, shunt nephritis, and visceral abscesses produce identical isolated low C3 patterns and must be excluded through blood cultures, hepatitis B/C/HIV serologies, and echocardiography before diagnosing primary C3 glomerulopathy. 2, 3

Combined Low C3 and C4

• Classical pathway activation with both C3 and C4 depression points strongly toward lupus nephritis or hepatitis C-associated mixed cryoglobulinemia, requiring cryoglobulin testing, rheumatoid factor, and hepatitis C serology. 2, 4

• Lupus nephritis shows low C3 in >92% of active cases, with anti-dsDNA antibodies (98% specificity) and "full-house" immunofluorescence (IgG, IgM, IgA, C3, C1q) on biopsy confirming the diagnosis. 4

Biopsy Immunofluorescence: The Definitive Decision Point

C3-Dominant Pattern (≥100-fold greater than immunoglobulin)

• C3 glomerulopathy diagnosis requires three mandatory exclusions before any immunosuppressive therapy: (1) active or prior infection through comprehensive infectious screening, (2) masked monoclonal deposits via pronase-digestion immunofluorescence when monoclonal protein is present, and (3) characterization of complement dysregulation through genetic and autoantibody testing. 3, 1

• Pronase-digestion immunofluorescence on paraffin-embedded tissue must be performed immediately when any circulating monoclonal protein is detected, because 5–10% of apparent C3 glomerulopathy cases are actually membranoproliferative glomerulonephritis with masked monoclonal deposits requiring clone-directed therapy instead of complement inhibition. 2, 3

• Electron microscopy differentiates C3 glomerulonephritis (ill-defined mesangial, subepithelial, subendothelial deposits) from dense deposit disease (highly electron-dense intramembranous "sausage-like" deposits), though both share alternative pathway dysregulation. 3

Immunoglobulin-Positive Pattern

• Immune complex-mediated MPGN with C3 co-deposition suggests classical pathway activation and requires thorough evaluation for underlying antigenemia triggers: infections (hepatitis B/C, endocarditis), autoimmune diseases (lupus, cryoglobulinemia), and monoclonal gammopathies in adults. 1

Specialized Complement Testing: When and What to Order

Comprehensive Alternative Pathway Assessment

• Genetic screening for mutations in C3, complement factors H, I, B, CD46 (membrane cofactor protein), and CFHR1-5 should be performed even when serum complement levels appear normal, because complement dysregulation can occur without hypocomplementemia. 1, 3, 5

• Acquired abnormalities include C3 nephritic factor (antibody to C3 convertase) and anti-factor H antibodies, which are more common in adults, whereas genetic mutations predominate in children. 1, 6

• C3 nephritic factor is detected significantly more frequently in dense deposit disease than other histological types and is present in approximately half of patients with CFH or CFI mutations. 5

• Many specialized complement tests are not routinely available in commercial laboratories and require sending samples to reference centers such as University of Iowa or National Jewish Health. 1, 2

Monoclonal Gammopathy Screening: A Critical Pitfall

• All adults with apparent C3 glomerulopathy, especially those ≥50 years, must be screened for monoclonal protein because 60–80% have a detectable monoclonal gammopathy at diagnosis, and roughly 30% of these have monoclonal proteins functioning as C3 nephritic factor or anti-factor H antibodies. 2, 3, 7

• Required screening tests: serum and urine protein electrophoresis with immunofixation plus serum free light-chain analysis, followed by hematology consultation to evaluate for MGUS, multiple myeloma, or lymphoproliferative disorders. 2, 3

• Failure to perform pronase-digestion immunofluorescence when monoclonal protein is present leads to misdiagnosis in 5–10% of cases, resulting in inappropriate complement-directed therapy when clone-directed therapy (bortezomib, rituximab) is actually required. 3

Treatment Algorithms Driven by C3 and Alternative Pathway Results

Infection-Related Disease (Identified Through C3 Pattern)

• Primary therapy is antimicrobial eradication of the underlying infection plus supportive measures (RAS inhibition, diuretics, antihypertensives); corticosteroids are reserved only for severe crescentic disease. 3

• Post-infectious glomerulonephritis typically resolves without immunosuppression once infection is treated, making this distinction from primary C3 glomerulopathy absolutely critical. 3

MGRS-Associated C3 Glomerulopathy

• Clone-directed therapy is the cornerstone when monoclonal protein is detected and confirmed by pronase-digestion immunofluorescence, requiring collaboration with hematology for bortezomib-based regimens, rituximab, or other clone-targeted agents. 3

Primary C3 Glomerulopathy (No Infection, No MGRS)

• Mild disease (preserved renal function, non-nephrotic proteinuria): RAS inhibition alone; immunosuppression should be avoided. 3

• Moderate disease (declining renal function, nephrotic-range proteinuria): First-line limited course of oral glucocorticoids (prednisone 1 mg/kg/day, max 60 mg, tapered over 3–6 months); if contraindicated, consider mycophenolate mofetil, rituximab, or cyclophosphamide. 3

• Calcineurin inhibitors must be avoided because long-term use causes immune-complex-negative angiopathy and thrombotic microangiopathy. 3

• Severe/crescentic disease: High-dose IV methylprednisolone (500–1000 mg daily × 3 days) followed by oral prednisone 1 mg/kg/day plus cyclophosphamide. 3

Prognostic Value of Alternative Pathway Assessment

• Genetic and acquired alternative pathway abnormalities are heterogeneous in C3 glomerulopathy, with the most common acquired abnormality being C3 nephritic factor and the most common genetic finding being H402 and V62 alleles of Factor H. 6

• A ≥40% decline in eGFR over 2–3 years predicts poor renal outcome in C3 glomerulopathy, making early identification through C3 and alternative pathway testing critical for prognostication. 3

• Both C3GN and dense deposit disease variants are progressive and recur in transplanted kidneys, with recurrence documented within 1 year of transplantation resulting in allograft function decline. 6, 7

Common Pitfalls and How to Avoid Them

• Pitfall: Assuming isolated low C3 automatically indicates C3 glomerulopathy. Solution: Confirm with kidney biopsy demonstrating C3-dominant immunofluorescence (≥100-fold greater than immunoglobulin) and exclude infection and monoclonal gammopathy first. 2, 3

• Pitfall: Skipping pronase-digestion immunofluorescence when monoclonal protein is present. Solution: Perform pronase digestion on all cases with any detectable monoclonal protein to avoid missing masked deposits in 5–10% of cases. 3

• Pitfall: Assuming normal serum C3 excludes complement-mediated disease. Solution: Perform comprehensive complement profiling (genetic and autoantibody testing) regardless of serum levels, because dysregulation can occur without hypocomplementemia. 3

• Pitfall: Delaying biopsy in presumed post-streptococcal glomerulonephritis. Solution: Proceed with biopsy if C3 remains low beyond 12 weeks, renal function worsens, or nephrotic-range proteinuria develops. 2

• Pitfall: Initiating immunosuppression before excluding infection. Solution: Complete infectious screening (hepatitis B/C, HIV, blood cultures, echocardiography when indicated) before any immunosuppressive therapy, because infection-related disease requires antimicrobials, not immunosuppression. 3